This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okamoto, M. Articles by Oyasu, R. Search for Related Content PubMed PubMed Citation Articles by Okamoto, M. Articles by Oyasu, R.

Interleukin-6 as a Paracrine and Autocrine Growth Factor in Human Prostatic Carcinoma Cells in Vitro¹

Departments of Pathology [M. O., R. O.] and Urology [C. L.], Northwestern University Medical School, Chicago, Illinois 60611-3008

Interleukin (IL)-6 plays a significant role in genitourinary carcinomas. The present study was conducted to define the role of IL-6 in the growth of prostatic carcinoma and benign prostatic hyperplasia (BPH). An in vitro experiment was carried out using human prostatic carcinoma cell lines (LNCaP, which is androgen sensitive and slow growing, and DU145 and PC3, which are androgen insensitive and fast growing), and primary human epithelial and stromal cells derived from BPH. Cells were treated with recombinant human IL-6 or conditioned medium (CM) derived from the above cultured cells to identify possible paracrine and autocrine pathways. LNCaP was clearly responsive to exogenous IL-6 and to the CM derived from stromal cells, but not to the CM from LNCaP cells (P < 0.001). DU145 and PC3 were slightly stimulated to grow by exogenous IL-6 and the CM derived from both stromal and respective homologous cells (P < 0.01). In contrast, BPH-derived epithelial cells showed little or no response to IL-6. The stimulatory effect of CM on prostatic carcinoma cells was significantly reduced by the addition of anti-IL-6 antibody to the culture medium. Furthermore, the growth of DU145 and PC3 in serum-free medium was also inhibited by anti-IL-6 antibody (P < 0.001). All cell lines tested, except for LNCaP, secreted IL-6 into the culture medium. Results of reverse transcriptase-PCR analysis indicated that IL-6 receptor mRNA was present in all carcinoma cell lines but not in epithelial cells or stromal cells derived from BPH. These results suggest that IL-6 functions as a paracrine growth factor for LNCaP and as an autocrine growth factor for DU145 and PC3, but it has no stimulatory effect on epithelial cells derived from BPH.

¹ This study was supported by NIH Grants CA14649, CA33511, and CA69851, the Joseph L. Mayberry Sr. Endowment Research Fund, and Northwestern University Medical Faculty Foundation Research Funds.

² To whom requests for reprints should be addressed, at Department of Pathology, Tarry 7-751, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, Illinois 60611-3008. Phone: (312) 503-8224; Fax: (312) 503-9830.

Received 2/20/96. Accepted 10/31/96.

This article has been cited by other articles:

				C.-H. Tang, J.-Y. Chuang, Y.-C. Fong, M.-C. Maa, T.-D. Way, and C.-H. Hung Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-{kappa}B pathways and promotes osteoclastogenesis in human oral cancer cells Carcinogenesis, August 1, 2008; 29(8): 1483 - 1492. [Abstract] [Full Text] [PDF]

				M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza Endocannabinoids in endocrine and related tumours Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408. [Abstract] [Full Text] [PDF]

				W. Zhao, M. Liu, and K. L. Kirkwood p38{alpha} Stabilizes Interleukin-6 mRNA via Multiple AU-rich Elements J. Biol. Chem., January 25, 2008; 283(4): 1778 - 1785. [Abstract] [Full Text] [PDF]

				A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer FASEB J, November 1, 2007; 21(13): 3763 - 3770. [Abstract] [Full Text] [PDF]

				Z. Li, Y. Chen, D. Cao, Y. Wang, G. Chen, S. Zhang, and J. Lu Glucocorticoid Up-Regulates Transforming Growth Factor-{beta} (TGF-{beta}) Type II Receptor and Enhances TGF-{beta} Signaling in Human Prostate Cancer PC-3 Cells Endocrinology, November 1, 2006; 147(11): 5259 - 5267. [Abstract] [Full Text] [PDF]

				J. Baillargeon, E. A. Platz, D. P. Rose, B. H. Pollock, D. P. Ankerst, S. Haffner, B. Higgins, A. Lokshin, D. Troyer, J. Hernandez, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1331 - 1335. [Abstract] [Full Text] [PDF]

				M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]

				D. R. Hodge, W. Xiao, B. Peng, J. C. Cherry, D. J. Munroe, and W. L. Farrar Enforced Expression of Superoxide Dismutase 2/Manganese Superoxide Dismutase Disrupts Autocrine Interleukin-6 Stimulation in Human Multiple Myeloma Cells and Enhances Dexamethasone-Induced Apoptosis Cancer Res., July 15, 2005; 65(14): 6255 - 6263. [Abstract] [Full Text] [PDF]

				J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6 Cancer Res., July 1, 2005; 65(13): 5965 - 5973. [Abstract] [Full Text] [PDF]

				D. J. George, S. Halabi, T. F. Shepard, B. Sanford, N. J. Vogelzang, E. J. Small, and P. W. Kantoff The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 Clin. Cancer Res., March 1, 2005; 11(5): 1815 - 1820. [Abstract] [Full Text] [PDF]

				M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]

				K.-i. Nakashiro, S. Hara, Y. Shinohara, M. Oyasu, H. Kawamata, S. Shintani, H. Hamakawa, and R. Oyasu Phenotypic Switch from Paracrine to Autocrine Role of Hepatocyte Growth Factor in an Androgen-Independent Human Prostatic Carcinoma Cell Line, CWR22R Am. J. Pathol., August 1, 2004; 165(2): 533 - 540. [Abstract] [Full Text] [PDF]

				C. N. Papandreou, D. D. Daliani, D. Nix, H. Yang, T. Madden, X. Wang, C. S. Pien, R. E. Millikan, S.-M. Tu, L. Pagliaro, et al. Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer J. Clin. Oncol., June 1, 2004; 22(11): 2108 - 2121. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				L. Jia, C. S-Y. Choong, C. Ricciardelli, J. Kim, W. D. Tilley, and G. A Coetzee Androgen Receptor Signaling: Mechanism of Interleukin-6 Inhibition Cancer Res., April 1, 2004; 64(7): 2619 - 2626. [Abstract] [Full Text] [PDF]

				M. Onuma, J. D. Bub, T. L. Rummel, and Y. Iwamoto Prostate Cancer Cell-Adipocyte Interaction: LEPTIN MEDIATES ANDROGEN-INDEPENDENT PROSTATE CANCER CELL PROLIFERATION THROUGH c-Jun NH2-TERMINAL KINASE J. Biol. Chem., October 24, 2003; 278(43): 42660 - 42667. [Abstract] [Full Text] [PDF]

				L. F. Zerbini, Y. Wang, J.-Y. Cho, and T. A Libermann Constitutive Activation of Nuclear Factor {kappa}B p50/p65 and Fra-1 and JunD Is Essential for Deregulated Interleukin 6 Expression in Prostate Cancer Cancer Res., May 1, 2003; 63(9): 2206 - 2215. [Abstract] [Full Text] [PDF]

				H. Steiner, S. Godoy-Tundidor, H. Rogatsch, A. P. Berger, D. Fuchs, B. Comuzzi, G. Bartsch, A. Hobisch, and Z. Culig Accelerated in Vivo Growth of Prostate Tumors that Up-Regulate Interleukin-6 Is Associated with Reduced Retinoblastoma Protein Expression and Activation of the Mitogen-Activated Protein Kinase Pathway Am. J. Pathol., February 1, 2003; 162(2): 655 - 663. [Abstract] [Full Text] [PDF]

				S. O. Lee, W. Lou, M. Hou, F. de Miguel, L. Gerber, and A. C. Gao Interleukin-6 Promotes Androgen-independent Growth in LNCaP Human Prostate Cancer Cells Clin. Cancer Res., January 1, 2003; 9(1): 370 - 376. [Abstract] [Full Text] [PDF]

				L. B. Mora, R. Buettner, J. Seigne, J. Diaz, N. Ahmad, R. Garcia, T. Bowman, R. Falcone, R. Fairclough, A. Cantor, et al. Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells Cancer Res., November 15, 2002; 62(22): 6659 - 6666. [Abstract] [Full Text] [PDF]

				V. Syed, G. Ulinski, S. C. Mok, and S.-M. Ho Reproductive Hormone-Induced, STAT3-Mediated Interleukin 6 Action in Normal and Malignant Human Ovarian Surface Epithelial Cells J Natl Cancer Inst, April 17, 2002; 94(8): 617 - 629. [Abstract] [Full Text] [PDF]

				T. Ueda, N. Bruchovsky, and M. D. Sadar Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways J. Biol. Chem., February 22, 2002; 277(9): 7076 - 7085. [Abstract] [Full Text] [PDF]

				P. D. Deeble, D. J. Murphy, S. J. Parsons, and M. E. Cox Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells Mol. Cell. Biol., December 15, 2001; 21(24): 8471 - 8482. [Abstract] [Full Text] [PDF]

				D. Giri, M. Ozen, and M. Ittmann Interleukin-6 Is an Autocrine Growth Factor in Human Prostate Cancer Am. J. Pathol., December 1, 2001; 159(6): 2159 - 2165. [Abstract] [Full Text] [PDF]

				K. Nishimura, N. Nonomura, E. Satoh, Y. Harada, M. Nakayama, T. Tokizane, T. Fukui, Y. Ono, H. Inoue, M. Shin, et al. Potential Mechanism for the Effects of Dexamethasone on Growth of Androgen-Independent Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1739 - 1746. [Abstract] [Full Text] [PDF]

				A. Hobisch, R. Ramoner, D. Fuchs, S. Godoy-Tundidor, G. Bartsch, H. Klocker, and Z. Culig Prostate Cancer Cells (LNCaP) Generated after Long-Term Interleukin 6 (IL-6) Treatment Express IL-6 and Acquire an IL-6 Partially Resistant Phenotype Clin. Cancer Res., September 1, 2001; 7(9): 2941 - 2948. [Abstract] [Full Text] [PDF]

				D.-L. Lin, M. C. Whitney, Z. Yao, and E. T. Keller Interleukin-6 Induces Androgen Responsiveness in Prostate Cancer Cells through Up-Regulation of Androgen Receptor Expression Clin. Cancer Res., June 1, 2001; 7(6): 1773 - 1781. [Abstract] [Full Text] [PDF]

				J. Nakashima, M. Tachibana, Y. Horiguchi, M. Oya, T. Ohigashi, H. Asakura, and M. Murai Serum Interleukin 6 as a Prognostic Factor in Patients with Prostate Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2702 - 2706. [Abstract] [Full Text]

				T. Chen, L. H. Wang, and W. L. Farrar Interleukin 6 Activates Androgen Receptor-mediated Gene Expression through a Signal Transducer and Activator of Transcription 3-dependent Pathway in LNCaP Prostate Cancer Cells Cancer Res., April 1, 2000; 60(8): 2132 - 2135. [Abstract] [Full Text]

				T. M. Moore, R. Garg, C. Johnson, M. J. Coptcoat, A. J. Ridley, and J. D. H. Morris PSK, a Novel STE20-like Kinase Derived from Prostatic Carcinoma That Activates the c-Jun N-terminal Kinase Mitogen-activated Protein Kinase Pathway and Regulates Actin Cytoskeletal Organization J. Biol. Chem., February 11, 2000; 275(6): 4311 - 4322. [Abstract] [Full Text] [PDF]

				T. Yamaguchi, H. Kimura, S. Yokota, Y. Yamamoto, T. Hashimoto, M. Nakagawa, M. Ito, and T. Ogura Effect of IL-6 Elevation in Malignant Pleural Effusion on Hyperfibrinogenemia in Lung Cancer Patients Jpn. J. Clin. Oncol., February 1, 2000; 30(2): 53 - 58. [Abstract] [Full Text] [PDF]

				A. C. Gao, W. Lou, and J. T. Isaacs Enhanced GBX2 Expression Stimulates Growth of Human Prostate Cancer Cells via Transcriptional Up-Regulation of the Interleukin 6 Gene Clin. Cancer Res., February 1, 2000; 6(2): 493 - 497. [Abstract] [Full Text]

				B. B. Moore, D. A. Arenberg, K. Stoy, T. Morgan, C. L. Addison, S. B. Morris, M. Glass, C. Wilke, Y. Y. Xue, S. Sitterding, et al. Distinct CXC Chemokines Mediate Tumorigenicity of Prostate Cancer Cells Am. J. Pathol., May 1, 1999; 154(5): 1503 - 1512. [Abstract] [Full Text] [PDF]

				T. Chen, R. W. Cho, P. J. S. Stork, and M. J. Weber Elevation of Cyclic Adenosine 3',5'-Monophosphate Potentiates Activation of Mitogen-activated Protein Kinase by Growth Factors in LNCaP Prostate Cancer Cells Cancer Res., January 1, 1999; 59(1): 213 - 218. [Abstract] [Full Text] [PDF]

				C. Rancourt, A. Piche, J. Gomez-Navarro, M. Wang, R. D. Alvarez, G. P. Siegal, G. M. Fuller, S. A. Jones, and D. T. Curiel Interleukin-6 Modulated Conditionally Replicative Adenovirus as an Antitumor/Cytotoxic Agent for Cancer Therapy Clin. Cancer Res., January 1, 1999; 5(1): 43 - 50. [Abstract] [Full Text] [PDF]

				Y. Qiu, D. Robinson, T. G. Pretlow, and H.-J. Kung Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells PNAS, March 31, 1998; 95(7): 3644 - 3649. [Abstract] [Full Text] [PDF]